A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Fedovapagon (Primary)
  • Indications Nocturia
  • Focus Registrational; Therapeutic Use
  • Acronyms EQUINOC
  • Sponsors Vantia Therapeutics
  • Most Recent Events

    • 03 Oct 2017 Results presented in a Vantia Therapeutics Media Release.
    • 03 Oct 2017 Primary endpoint has been met. (Change in mean patient reported nocturia bother score), according to a Vantia Therapeutics media release.
    • 03 Oct 2017 Primary endpoint has been met (Change in the mean number of night-time voids), according to a Vantia Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top